 |
市場調查報告書
商品編碼
2130452
全球癌症和腫瘤分析市場（至2031年）：按產品和服務（儀器和系統、檢測和試劑盒、服務）、技術（NGS、PCR、IHC、ISH/FISH）、檢體類型、應用、癌症類型、最終用戶和地區分類Cancer Tumor Profiling Market by Product & Service Offering (Instruments/Systems, Assays/Kits, Services), Technology (NGS, PCR, IHC, ISH/FISH), Sample Type, Application, Cancer Type, End User & Region - Global Forecast to 2031 |
||||||
價格
癌症和腫瘤分析市場預計將從 2026 年的 120.2 億美元成長到 2031 年的 198.7 億美元，複合年成長率為 10.6%。
受癌症發病率上升、分子標靶療法和免疫療法獲批數量增加以及分子分型在常規癌症診療中應用日益廣泛等因素的推動，全球癌症和腫瘤分析市場預計在預測期內將保持強勁成長。此外，次世代定序(NGS)、聚合酵素鏈鎖反應(PCR)、免疫組織化學 (IHC)、原位雜合反應(ISH)、液態生物檢體和生物資訊學等技術的進步，以及對腫瘤全面表徵、治療選擇、治療反應監測、復發檢測和基於生物標記的臨床試驗日益成長的需求，也進一步促進了市場成長。
另一方面，檢測開發和驗證的高昂成本、複雜的法規核准流程、報銷限制、數據解釋的難度以及先進分子檢測基礎設施可用性的區域差異，預計將在一定程度上抑制市場成長。
| 調查範圍 | |
|---|---|
| 調查期 | 2026-2031 |
| 基準年 | 2025 |
| 預測期 | 2026-2031 |
| 單元 | 金額（美元） |
| 部分 | 供應類別、技術、檢體、應用程式、癌症類型、最終用戶 |
| 目標區域 | 北美、歐洲、亞太地區、拉丁美洲、中東和非洲 |
“按產品類別分類，檢測產品、試劑盒、試劑和耗材將在 2025 年佔據最大的市場佔有率。”
由於這些組件在組織和血液分析工作流程中的持續應用，它們將在2025年佔據最大的市場佔有率。定序試劑、PCR耗材、抗體、探針、檢體製備試劑盒和其他檢測組件是患者間檢測所必需的，這將推動銷售的持續成長。它們與高通量平台的兼容性以及在診斷、分子表徵、治療選擇和臨床研究等領域的日益廣泛的應用，進一步鞏固了該領域的主導地位。
“從技術角度來看，到 2025 年，次世代定序將佔據最大的市場佔有率。”
這項技術之所以佔據最大的市場佔有率，是因為它能夠同時分析多個基因和基因組突變，檢測罕見和共存的生物標記物，並支持對組織和血液檢體進行全面的基因組分析。隨著廣泛腫瘤檢測、伴隨診斷檢測和液態生物檢體工作流程的日益普及，以及臨床試驗中對可擴展分子分析需求的不斷成長，預計在預測期內，這項技術將進一步鞏固其主導地位。
“預計亞太地區在2026年至2031年間將錄得最高的複合年成長率。”
推動這一成長的主要因素包括癌症發病率上升、癌症治療基礎設施不斷完善、分子診斷投資增加以及精準醫療的日益普及。此外，新一代定序（NGS）和液態切片檢測的可及性提高、製藥公司臨床試驗的增加、區域基因組檢測設施的建設，以及全球和本土診斷公司在中國、日本、印度、韓國、澳洲和東南亞等地的日益活躍，也促進了市場成長。
本報告考察了全球癌症和腫瘤分析市場，提供了市場概述、影響市場成長的各種因素分析、技術和專利趨勢、法律制度、案例研究、歷史和預測的市場規模、按各個細分市場和地區/主要國家進行的詳細分析、競爭格局以及主要公司的概況。
目錄
第1章：引言
第2章執行摘要
第3章重要考察
第4章 市場概覽
- 市場動態
- 促進因素
- 抑制因子
- 機會
- 任務
- 未滿足的需求和閒置頻段
- 與相關市場和不同產業相關的跨領域機遇
- 一級/二級/三級公司的策略性舉措
第5章 產業趨勢
- 波特五力分析
- 總體經濟指標
- GDP趨勢與預測
- 全球癌症和腫瘤分析產業的趨勢
- 供應鏈分析
- 價值鏈分析
- 生態系分析
- 價格分析
- 貿易分析
- 2026-2027 年主要會議和活動
- 影響客戶業務的趨勢/顛覆性因素
- 投資和資金籌措場景
- 2025年美國關稅對伴隨診斷市場的影響
第6章：技術進步、人工智慧的影響、專利、創新與未來應用
- 主要新興技術
- 高靈敏度液態切片錯誤校正定序
- 空間、單細胞和多重組織分析
- 互補技術
- 人工智慧賦能的生物資訊學和臨床決策支持
- 數位病理學和影像分析
- 鄰近技術
- 分子影像和放射組學
- 技術/產品藍圖
- 專利分析
- 未來應用
- 人工智慧/生成式人工智慧對癌症和腫瘤分析市場的影響
第7章永續性和監管情勢
- 區域法規和合規性
- 對永續性的承諾
第8章：顧客趨勢與購買行為
- 決策流程
- 相關人員及購買評估標準
- 實施障礙和內部挑戰
- 各個終端用戶產業尚未滿足的需求
- 市場盈利
第9章 癌症和腫瘤分析市場：按產品和服務分類
- 產品
- 測量儀器和系統
- 檢測方法、試劑盒、試劑、耗材
- 服務
- 臨床腫瘤學特徵分析檢測服務
- 生物製藥、臨床試驗、伴隨診斷服務
第10章 癌症和腫瘤分析市場：按檢體類型分類
- 組織檢體
- 組織切片檢查
- 血液檢體
- 液態生物檢體
- 骨髓
- 用於研究和臨床試驗的檢體
- 其他檢體類型
第11章 癌症和腫瘤分析市場：按應用領域分類
- 臨床
- 癌症診斷、分子特徵分析、預後及風險評估
- 治療方案和伴隨診斷
- 監測治療反應和抗藥性
- 殘留病灶、治療後監測、復發檢測
- 研究與開發
- 生物標記、標靶、早期藥物發現
- 臨床前開發和驗證
- 臨床試驗、病患分層、受試者登記
第12章 癌症和腫瘤分析市場：按癌症類型分類
- 固態腫瘤
- 肺癌
- 乳癌
- 結腸癌
- 攝護腺癌
- 婦科癌症
- 黑色素瘤
- 腦部和中樞神經系統腫瘤
- 頭頸癌
- 其他固態腫瘤
- 血液系統惡性腫瘤/骨髓惡性腫瘤
- 白血病
- 淋巴瘤
- 多發性骨髓瘤及其他體液腫瘤
第13章 癌症和腫瘤分析市場：按最終用戶分類
- 醫院、癌症中心、腫瘤診所
- 綜合醫院
- 癌症醫院和癌症中心
- 獨立且專業的參考實驗室
- 製藥和生物技術公司
- 委外研發機構（CRO）/中心實驗室
- 其他最終用戶
第14章 癌症和腫瘤分析市場：按地區分類
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他
- 亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 其他
- 拉丁美洲
- 巴西
- 墨西哥
- 其他
- 中東和非洲
- 海灣合作理事會國家
- 其他
第15章 競爭格局
- 主要參與企業的策略/優勢
- 收入分析
- 市佔率分析
- 企業估值矩陣：主要公司
- 公司估值矩陣：新創企業/中小企業
- 企業估值和財務指標
- 品牌/產品對比
- 競爭格局
第16章：公司簡介
- 大公司
- F. HOFFMANN-LA ROCHE LTD.
- ILLUMINA, INC.
- THERMO FISHER SCIENTIFIC INC.
- QIAGEN
- GUARDANT HEALTH
- LABCORP
- ABBOTT
- TEMPUS AI, INC.
- NATERA, INC.
- NEOGENOMICS LABORATORIES, INC
- MYRIAD GENETICS, INC.
- AGILENT TECHNOLOGIES, INC
- QUEST DIAGNOSTICS
- CARIS LIFE SCIENCES, INC.
- DANAHER
- 其他公司
- INSIGHT MOLECULAR DIAGNOSTICS, INC (IMDX) (ONCOCYTE CORPORATION)
- ONCODNA SA
- MOLECULAR HEALTH GMBH
- ALMAC DIAGNOSTIC SERVICES (THE ALMAC GROUP)
- INVIVOSCRIBE, INC.
- ACT GENOMICS CO., LTD.
- LUCENCE HEALTH INC
- GC GENOME CORPORATION
- MEDGENOME LABS LTD.
- MGI TECH CO., LTD.
第17章調查方法
第18章附錄
Product Code: MD 4803
The cancer tumor profiling market is projected to reach USD 19.87 billion by 2031 from USD 12.02 billion in 2026, at a CAGR of 10.6%. The global cancer tumor profiling market is projected to witness strong growth during the forecast period, supported by rising cancer incidence, increasing approvals of targeted therapies and immunotherapies, and growing integration of molecular profiling into routine oncology care. Market expansion is further supported by advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), liquid biopsy, and bioinformatics, along with increasing demand for comprehensive tumor characterization, treatment selection, treatment-response monitoring, recurrence detection, and biomarker-driven clinical trials. However, high assay-development and validation costs, complex regulatory pathways, reimbursement limitations, data-interpretation complexity, and uneven availability of advanced molecular testing infrastructure across regions are expected to restrain market growth to some extent.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Offering, Technology, Sample Type, Application, Cancer Type, End User |
| Regions covered | North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa |
"Assays, kits, reagents, and consumables accounted for the largest share of the cancer tumor profiling market, by offering, in 2025."
Based on offering, the cancer tumor profiling market is segmented into products and services. Products include instruments and systems; and assays, kits, reagents, and consumables. Services include clinical tumor profiling testing services and biopharmaceutical, clinical-trial, and companion diagnostic services. In 2025, assays, kits, reagents, and consumables accounted for the largest share due to their recurring use across tissue and blood-based profiling workflows. Sequencing reagents, PCR consumables, antibodies, probes, sample-preparation kits, and other assay components are required for each patient test, creating sustained pull-through revenue. Their compatibility with high-throughput platforms and expanding use in diagnosis, molecular characterization, treatment selection, and clinical research further support the leading position of this segment.
"Next-generation sequencing accounted for the largest share of the cancer tumor profiling market, by technology, in 2025."
Based on technology, the global cancer tumor profiling market is segmented into next-generation sequencing; polymerase chain reaction, including qPCR, RT-PCR, and digital PCR; immunohistochemistry; in situ hybridization, including FISH, CISH, and SISH; and other tumor profiling technologies. In 2025, next-generation sequencing accounted for the largest share because of its ability to analyze multiple genes and genomic alterations simultaneously, detect rare and co-occurring biomarkers, and support comprehensive genomic profiling from tissue and blood samples. Increasing use of broad oncology panels, companion diagnostic assays, and liquid-biopsy workflows, together with growing demand for scalable molecular profiling in clinical trials, is expected to reinforce the segment's leading position during the forecast period.
"The Asia Pacific region is projected to grow at the highest CAGR in the cancer tumor profiling market from 2026 to 2031."
The cancer tumor profiling market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is projected to register the highest CAGR due to rising cancer incidence, expanding oncology infrastructure, increasing investment in molecular diagnostics, and growing adoption of precision-medicine approaches. Growth is further supported by improving access to NGS and liquid-biopsy testing, expansion of pharmaceutical clinical trials, establishment of regional genomic laboratories, and the increasing presence of global and domestic diagnostics companies across China, Japan, India, South Korea, Australia, and Southeast Asia.
List of Companies Profiled in the Report
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- Guardant Health, Inc.
- Tempus AI, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Laboratory Corporation of America Holdings (Labcorp)
- Abbott Laboratories
- Natera, Inc.
- NeoGenomics, Inc.
- Myriad Genetics, Inc.
- Agilent Technologies, Inc.
- Quest Diagnostics Incorporated
- Caris Life Sciences, Inc.
- Danaher Corporation
Research Coverage
This research report categorizes the cancer tumor profiling market by offering, technology, sample type, application, cancer type, end user, and region. The report provides detailed information on major market factors, including drivers, restraints, opportunities, and challenges. It analyzes leading industry participants and provides insights into their business overviews, product and service portfolios, technology capabilities, market positions, and key strategies, including product launches and approvals, partnerships, collaborations, agreements, acquisitions, expansions, and other recent developments. The report also covers regulatory trends, reimbursement considerations, precision-oncology adoption, biomarker-testing practices, and emerging technologies such as liquid biopsy, minimal residual disease testing, AI-enabled interpretation, spatial biology, and multi-omics. In addition, it evaluates established companies and emerging participants across the global cancer tumor profiling ecosystem.
Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing close approximations of revenue for the overall cancer tumor profiling market and its subsegments. It will help stakeholders understand the competitive landscape, identify high-growth opportunities, assess technology and regional trends, and formulate effective product, partnership, investment, and go-to-market strategies. The report also provides an integrated view of the market pulse, covering key drivers, restraints, opportunities, and challenges.
The report provides insights into the following points:
- Analysis of key drivers, including increasing adoption of precision oncology and targeted therapies, expansion of NGS-based comprehensive genomic profiling, rising use of liquid biopsy, growing cancer incidence, and increasing pharmaceutical-diagnostic collaborations. The report also examines restraints such as high development and validation costs, reimbursement limitations, and data-interpretation complexity, as well as challenges related to regulatory requirements, standardization, and limited testing infrastructure in emerging markets.
- Product Development/Innovation: Detailed insights into newly launched and pipeline tumor profiling assays, sequencing platforms, pathology solutions, liquid-biopsy tests, companion diagnostics, minimal residual disease solutions, AI-enabled interpretation tools, and integrated molecular testing workflows.
- Market Development: Comprehensive information on attractive markets and growth opportunities across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, including country-level adoption patterns and regional expansion strategies.
- Market Diversification: Exhaustive information on product and service portfolios, technology developments, regulatory approvals, pharmaceutical partnerships, clinical-trial collaborations, acquisitions, laboratory expansions, and investments in the cancer tumor profiling market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, technology capabilities, clinical testing footprints, and service offerings of leading players, including F. Hoffmann-La Roche AG, Guardant Health, Inc., Illumina, Inc., Tempus AI, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Laboratory Corporation of America Holdings, Natera, Inc., NeoGenomics, Inc., Myriad Genetics, Inc., Agilent Technologies, Inc., Quest Diagnostics Incorporated, Caris Life Sciences, Inc., Abbott Laboratories, and Danaher Corporation.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 CANCER/TUMOR PROFILING MARKET OVERVIEW
- 3.2 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2026 VS. 2031
- 3.3 CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2026 VS. 2031
- 3.4 CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2026 VS. 2031
- 3.5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2026 VS. 2031
- 3.6 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2026 VS. 2031
- 3.7 CANCER/TUMOR PROFILING MARKET, BY APPLICATION TYPE, 2026 VS. 2031
- 3.8 CANCER/TUMOR PROFILING MARKET, BY CLINICAL APPLICATION TYPE, 2026 VS. 2031
- 3.9 CANCER/TUMOR PROFILING MARKET, BY RESEARCH AND DRUG DEVELOPMENT APPLICATION, 2026 VS. 2031
- 3.10 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2026 VS. 2031
- 3.11 CANCER/TUMOR PROFILING MARKET, BY SOLID TUMOR TYPE, 2026 VS. 2031
- 3.12 CANCER/TUMOR PROFILING MARKET, BY LIQUID TUMOR, 2026 VS. 2031
- 3.13 CANCER/TUMOR PROFILING MARKET, BY END USER, 2026 VS. 2031
- 3.14 CANCER/TUMOR PROFILING MARKET, BY HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS, 2026 VS. 2031
- 3.15 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Increasing adoption of precision oncology and targeted therapies
- 4.2.1.2 Rising adoption of comprehensive genomic profiling and NGS-based testing
- 4.2.1.3 Increasing cancer incidence and demand for molecular characterization
- 4.2.2 RESTRAINTS
- 4.2.2.1 High development, clinical validation, and regulatory approval costs
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Expansion of liquid biopsy and minimally invasive tumor profiling
- 4.2.3.2 AI-driven biomarker interpretation and digital pathology integration
- 4.2.4 CHALLENGES
- 4.2.4.1 Regulatory complexity associated with multi-analyte tumor profiling tests
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS & WHITE SPACES
- 4.3.1 UNMET NEEDS IN CANCER/TUMOR PROFILING MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
- 4.5.1 KEY MOVES & STRATEGIC FOCUS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC INDICATORS
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS & FORECAST
- 5.2.3 TRENDS IN GLOBAL CANCER/TUMOR PROFILING INDUSTRY
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 CANCER/TUMOR PROFILING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY KEY PLAYER, 2024-2026
- 5.6.2 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY REGION, 2024-2026
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 3822)
- 5.7.2 EXPORT SCENARIO (HS CODE 3822)
- 5.8 KEY CONFERENCES & EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.10 INVESTMENT & FUNDING SCENARIO
- 5.11 IMPACT OF 2025 US TARIFFS ON COMPANION DIAGNOSTICS MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON REGIONS
- 5.11.4.1 North America
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END-USE INDUSTRIES
- 5.11.5.1 Hospitals, Cancer Centers, and Oncology Clinics
- 5.11.5.2 Independent and Specialty Reference Laboratories
- 5.11.5.3 Pharmaceutical and Biotechnology Companies
- 5.11.5.4 Other end user
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.1.1 HIGH-SENSITIVITY LIQUID BIOPSY AND ERROR-CORRECTED SEQUENCING
- 6.1.2 SPATIAL, SINGLE-CELL, AND MULTIPLEX TISSUE PROFILING
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 AI-ENABLED BIOINFORMATICS AND CLINICAL DECISION SUPPORT
- 6.2.2 DIGITAL PATHOLOGY AND IMAGE ANALYSIS
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 MOLECULAR IMAGING AND RADIOMICS
- 6.4 TECHNOLOGY/PRODUCT ROADMAP
- 6.5 PATENT ANALYSIS
- 6.6 FUTURE APPLICATIONS
- 6.7 IMPACT OF AI/GENERATIVE AI ON CANCER/TUMOR PROFILING MARKET
- 6.7.1 INTRODUCTION
- 6.7.2 TOP USE CASES & MARKET POTENTIAL
- 6.7.3 KEY COMPANIES IMPLEMENTING AI
- 6.7.4 FUTURE OF AI
7 SUSTAINABILITY & REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS & COMPLIANCE
- 7.1.1 REGULATORY ANALYSIS
- 7.1.1.1 North America
- 7.1.1.1.1 US
- 7.1.1.1.2 Canada
- 7.1.1.2 Europe
- 7.1.1.2.1 Germany
- 7.1.1.2.2 UK
- 7.1.1.2.3 France
- 7.1.1.2.4 Italy
- 7.1.1.3 Asia Pacific
- 7.1.1.3.1 China
- 7.1.1.3.2 Japan
- 7.1.1.3.3 India
- 7.1.1.3.4 Australia
- 7.1.1.4 Latin America
- 7.1.1.4.1 Brazil
- 7.1.1.4.2 Mexico
- 7.1.1.5 Middle East
- 7.1.1.5.1 Africa
- 7.1.1.1 North America
- 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.1 REGULATORY ANALYSIS
- 7.2 SUSTAINABILITY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
- 7.2.1.1 Eco-friendly initiatives
- 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
- 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
9 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING
- 9.1 INTRODUCTION
- 9.2 PRODUCTS
- 9.2.1 INSTRUMENTS AND SYSTEMS
- 9.2.1.1 Decentralized molecular testing and pressure to cut turnaround time to drive instrument demand
- 9.2.2 ASSAYS, KITS, REAGENTS, AND CONSUMABLES
- 9.2.2.1 Recurring-use model to link procedure volume directly to revenue
- 9.2.1 INSTRUMENTS AND SYSTEMS
- 9.3 SERVICES
- 9.3.1 CLINICAL TUMOR PROFILING TESTING SERVICES
- 9.3.1.1 Rising clinical oncology tests and high selling prices to drive services growth
- 9.3.2 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES
- 9.3.2.1 Expanding oncology drug development to require broader biomarker adoption
- 9.3.1 CLINICAL TUMOR PROFILING TESTING SERVICES
10 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE
- 10.1 INTRODUCTION
- 10.2 TISSUE SAMPLES
- 10.2.1 TISSUE BIOPSY
- 10.3 BLOOD SAMPLES
- 10.3.1 LIQUID BIOPSY
- 10.4 BONE MARROW
- 10.4.1 RESEARCH AND CLINICAL-TRIAL SPECIMENS
- 10.5 OTHER SAMPLE TYPES
11 CANCER/TUMOR PROFILING MARKET, BY APPLICATION
- 11.1 INTRODUCTION
- 11.2 CLINICAL APPLICATIONS
- 11.2.1 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT
- 11.2.1.1 Integration of multi-omic biomarkers to redefine tumor diagnosis and classification
- 11.2.2 TREATMENT SELECTION AND COMPANION DIAGNOSTICS
- 11.2.2.1 Expanding targeted-therapy pipelines and pharma-diagnostic partnerships to drive companion diagnostics
- 11.2.3 TREATMENT-RESPONSE AND RESISTANCE MONITORING
- 11.2.3.1 Growing on-therapy profiling to monitor response and emerging resistance
- 11.2.4 RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION
- 11.2.4.1 Rising molecular residual disease testing to detect recurrence early
- 11.2.1 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT
- 11.3 RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS
- 11.3.1 BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY
- 11.3.1.1 Wider use of whole-exome, transcriptome, and proteomic profiling to accelerate drug discovery
- 11.3.2 PRECLINICAL DEVELOPMENT AND VALIDATION
- 11.3.2.1 Molecular profiling of preclinical models to validate targets and characterize resistance
- 11.3.3 CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT
- 11.3.3.1 Growing number of oncology clinical trials to embed biomarker profiling
- 11.3.1 BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY
12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE
- 12.1 INTRODUCTION
- 12.2 SOLID TUMORS
- 12.2.1 LUNG CANCER
- 12.2.1.1 Broad actionable biomarkers to drive high molecular testing in lung cancer
- 12.2.2 BREAST CANCER
- 12.2.2.1 High incidence and complex molecular classification to expand breast cancer profiling
- 12.2.3 COLORECTAL CANCER
- 12.2.3.1 Established biomarkers and emerging MRD testing to expand colorectal cancer profiling
- 12.2.4 PROSTATE CANCER
- 12.2.4.1 Growing HRR-targeted therapies to broaden profiling in metastatic prostate cancer
- 12.2.5 GYNECOLOGIC CANCERS
- 12.2.5.1 HRD/BRCA testing and endometrial molecular stratification to drive gynecologic profiling
- 12.2.6 MELANOMA
- 12.2.6.1 BRAF testing and immunotherapy biomarkers to sustain melanoma profiling
- 12.2.7 BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS
- 12.2.7.1 Molecular criteria in WHO definitions to make profiling essential for CNS tumors
- 12.2.8 HEAD AND NECK CANCERS
- 12.2.8.1 Rising immunotherapy use and PD-L1 testing to expand head and neck cancer profiling
- 12.2.9 OTHER SOLID TUMORS
- 12.2.1 LUNG CANCER
- 12.3 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES
- 12.3.1 LEUKEMIA
- 12.3.1.1 Routine molecular diagnosis and frequent MRD monitoring to drive leukemia profiling
- 12.3.2 LYMPHOMAS
- 12.3.2.1 Complex classification and growing genomic testing to broaden lymphoma profiling
- 12.3.3 MULTIPLE MYELOMA AND OTHER LIQUID TUMORS
- 12.3.3.1 NGS and sensitive MRD assays to create repeat testing in multiple myeloma
- 12.3.1 LEUKEMIA
13 CANCER/TUMOR PROFILING MARKET, BY END USER
- 13.1 INTRODUCTION
- 13.2 HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS
- 13.2.1 MULTISPECIALTY HOSPITALS
- 13.2.1.1 Growing integration of biomarker testing to embed profiling in hospital oncology pathways
- 13.2.2 DEDICATED CANCER HOSPITALS AND CANCER CENTERS
- 13.2.2.1 High oncology volumes and research programs to drive profiling at cancer centers
- 13.2.1 MULTISPECIALTY HOSPITALS
- 13.3 INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES
- 13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
- 13.5 CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES
- 13.6 OTHER END USERS
14 CANCER/TUMOR PROFILING MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 US
- 14.2.1.1 Advanced clinical genomics infrastructure and broad regulatory approvals to augment market growth
- 14.2.2 CANADA
- 14.2.2.1 Public funding of molecular profiling and expansion of national genomics capabilities to support growth
- 14.2.1 US
- 14.3 EUROPE
- 14.3.1 GERMANY
- 14.3.1.1 Strong molecular tumor board networks and multi-omic precision oncology infrastructure to drive adoption
- 14.3.2 UK
- 14.3.2.1 NHS-funded genomic testing and centralized genomic laboratory network to support market maturity
- 14.3.3 FRANCE
- 14.3.3.1 National genomic medicine infrastructure to accelerate tumor profiling
- 14.3.4 ITALY
- 14.3.4.1 Public funding for NGS and genomic testing to support precision-oncology expansion
- 14.3.5 SPAIN
- 14.3.5.1 National genomic test catalog and strong oncology research network to support market growth
- 14.3.6 REST OF EUROPE
- 14.3.1 GERMANY
- 14.4 ASIA PACIFIC
- 14.4.1 CHINA
- 14.4.1.1 Large cancer burden and formalization of clinical NGS standards to drive market expansion
- 14.4.2 JAPAN
- 14.4.2.1 National insurance coverage and C-CAT infrastructure to support broad CGP adoption
- 14.4.3 INDIA
- 14.4.3.1 Rising cancer burden and expansion of indigenous genomic infrastructure to support high growth
- 14.4.4 SOUTH KOREA
- 14.4.4.1 Government-backed NGS precision-oncology programs to accelerate clinical adoption
- 14.4.5 AUSTRALIA
- 14.4.5.1 National genomics framework and government investments to strengthen precision oncology
- 14.4.6 REST OF ASIA PACIFIC
- 14.4.1 CHINA
- 14.5 LATIN AMERICA
- 14.5.1 BRAZIL
- 14.5.1.1 National genomics program and local tumor atlas development to accelerate precision oncology
- 14.5.2 MEXICO
- 14.5.2.1 Expansion of national cancer genotyping infrastructure to support market development
- 14.5.3 REST OF LATIN AMERICA
- 14.5.1 BRAZIL
- 14.6 MIDDLE EAST & AFRICA
- 14.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
- 14.7 GCC COUNTRIES
- 14.7.1 GOVERNMENT-LED GENOMICS AND PRECISION-MEDICINE INVESTMENTS TO CREATE HIGH-GROWTH OPPORTUNITIES
- 14.8 REST OF MIDDLE EAST & AFRICA
- 14.8.1 LARGE UNMET NEED FOR BIOMARKER TESTING AND GRADUAL BUILD-OUT OF MOLECULAR ONCOLOGY CAPACITY
15 COMPETITIVE LANDSCAPE
- 15.1 INTRODUCTION
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER/TUMOR PROFILING MARKET
- 15.3 REVENUE ANALYSIS, 2023-2025
- 15.4 MARKET SHARE ANALYSIS, 2025
- 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 15.5.5.1 Company footprint
- 15.5.5.2 Regional footprint
- 15.5.5.3 Product & service footprint
- 15.5.5.4 Technology footprint
- 15.5.5.5 Sample Type footprint
- 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.1 PROGRESSIVE COMPANIES
- 15.6.2 RESPONSIVE COMPANIES
- 15.6.3 DYNAMIC COMPANIES
- 15.6.4 STARTING BLOCKS
- 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.5.1 Detailed list of key startups/SMEs
- 15.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
- 15.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
- 15.7 COMPANY VALUATION & FINANCIAL METRICS
- 15.7.1 FINANCIAL METRICS
- 15.7.2 COMPANY VALUATION
- 15.8 BRAND/PRODUCT COMPARISON
- 15.9 COMPETITIVE SCENARIO
- 15.9.1 PRODUCT LAUNCHES & APPROVALS
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
- 15.9.4 OTHER DEVELOPMENTS
16 COMPANY PROFILES
- 16.1 KEY PLAYERS
- 16.1.1 F. HOFFMANN-LA ROCHE LTD.
- 16.1.1.1 Business overview
- 16.1.1.2 Products offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product launches & approvals
- 16.1.1.3.2 Deals
- 16.1.1.3.3 Expansions
- 16.1.1.4 MnM view
- 16.1.1.4.1 Key strengths
- 16.1.1.4.2 Strategic choices
- 16.1.1.4.3 Weaknesses & competitive threats
- 16.1.2 ILLUMINA, INC.
- 16.1.2.1 Business overview
- 16.1.2.2 Products offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Product launches & approvals
- 16.1.2.3.2 Deals
- 16.1.2.3.3 Other developments
- 16.1.2.4 MnM view
- 16.1.2.4.1 Key strengths
- 16.1.2.4.2 Strategic choices
- 16.1.2.4.3 Weaknesses & competitive threats
- 16.1.3 THERMO FISHER SCIENTIFIC INC.
- 16.1.3.1 Business overview
- 16.1.3.2 Products offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Product launches
- 16.1.3.3.2 Deals
- 16.1.3.4 MnM view
- 16.1.3.4.1 Key strengths
- 16.1.3.4.2 Strategic choices
- 16.1.3.4.3 Weaknesses & competitive threats
- 16.1.4 QIAGEN
- 16.1.4.1 Business overview
- 16.1.4.2 Products offered
- 16.1.4.3 Recent developments
- 16.1.4.3.1 Product launches & approvals
- 16.1.4.3.2 Deals
- 16.1.4.3.3 Expansions
- 16.1.4.4 MnM view
- 16.1.4.4.1 Key strengths
- 16.1.4.4.2 Strategic choices
- 16.1.4.4.3 Weaknesses & competitive threats
- 16.1.5 GUARDANT HEALTH
- 16.1.5.1 Business overview
- 16.1.5.2 Products offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Product launches & approvals
- 16.1.5.4 MnM view
- 16.1.5.4.1 Key strengths
- 16.1.5.4.2 Strategic choices
- 16.1.5.4.3 Weaknesses & competitive threats
- 16.1.6 LABCORP
- 16.1.6.1 Business overview
- 16.1.6.2 Product & Services offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Service Launches, and Approvals
- 16.1.6.3.2 Deals
- 16.1.6.3.3 Expansions
- 16.1.7 ABBOTT
- 16.1.7.1 Business overview
- 16.1.7.2 Products offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Product approvals
- 16.1.7.3.2 Deals
- 16.1.8 TEMPUS AI, INC.
- 16.1.8.1 Business overview
- 16.1.8.2 Products offered
- 16.1.8.3 Recent developments
- 16.1.8.3.1 Product approvals
- 16.1.8.3.2 Deals
- 16.1.8.3.3 Other developments
- 16.1.9 NATERA, INC.
- 16.1.9.1 Business overview
- 16.1.9.2 Products offered
- 16.1.9.3 Recent developments
- 16.1.9.3.1 Product launches & Approvals
- 16.1.9.3.2 Deals
- 16.1.9.3.3 Expansions
- 16.1.9.3.4 Other developments
- 16.1.10 NEOGENOMICS LABORATORIES, INC
- 16.1.10.1 Business overview
- 16.1.10.2 Products offered
- 16.1.10.3 Recent developments
- 16.1.10.3.1 Product launches & approvals
- 16.1.10.3.2 Deals
- 16.1.10.3.3 Expansions
- 16.1.11 MYRIAD GENETICS, INC.
- 16.1.11.1 Business overview
- 16.1.11.2 Products offered
- 16.1.11.3 Recent developments
- 16.1.11.3.1 Product launches & approvals
- 16.1.11.3.2 Deals
- 16.1.12 AGILENT TECHNOLOGIES, INC
- 16.1.12.1 Business overview
- 16.1.12.2 Products offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Product launches & approvals
- 16.1.12.3.2 Deals
- 16.1.12.3.3 Expansions
- 16.1.13 QUEST DIAGNOSTICS
- 16.1.13.1 Business overview
- 16.1.13.2 Products/Services/Solutions offered
- 16.1.13.3 Recent developments
- 16.1.13.3.1 Product/Services launches & approvals
- 16.1.13.3.2 Deals
- 16.1.14 CARIS LIFE SCIENCES, INC.
- 16.1.14.1 Business overview
- 16.1.14.2 Products offered
- 16.1.14.3 Recent developments
- 16.1.14.3.1 Product launches & approvals
- 16.1.14.3.2 Deals
- 16.1.15 DANAHER
- 16.1.15.1 Business overview
- 16.1.15.2 Products offered
- 16.1.15.3 Recent developments
- 16.1.15.3.1 Deals
- 16.1.1 F. HOFFMANN-LA ROCHE LTD.
- 16.2 OTHER PLAYERS
- 16.2.1 INSIGHT MOLECULAR DIAGNOSTICS, INC (IMDX) (ONCOCYTE CORPORATION)
- 16.2.2 ONCODNA SA
- 16.2.3 MOLECULAR HEALTH GMBH
- 16.2.4 ALMAC DIAGNOSTIC SERVICES (THE ALMAC GROUP)
- 16.2.5 INVIVOSCRIBE, INC.
- 16.2.6 ACT GENOMICS CO., LTD.
- 16.2.7 LUCENCE HEALTH INC
- 16.2.8 GC GENOME CORPORATION
- 16.2.9 MEDGENOME LABS LTD.
- 16.2.10 MGI TECH CO., LTD.
17 RESEARCH METHODOLOGY
- 17.1 RESEARCH DATA
- 17.1.1 SECONDARY DATA
- 17.1.1.1 List of secondary sources
- 17.1.1.2 Key data from secondary sources
- 17.1.2 PRIMARY DATA
- 17.1.2.1 List of primary sources
- 17.1.2.2 Key data from primary sources
- 17.1.2.3 Key industry insights
- 17.1.2.4 Breakdown of primary interviews
- 17.1.1 SECONDARY DATA
- 17.2 MARKET SIZE ESTIMATION
- 17.2.1 TOTAL MARKET SIZE: CANCER/TUMOR PROFILING MARKET
- 17.2.2 BOTTOM-UP APPROACH
- 17.2.2.1 Approach 1: Revenue estimation of key players
- 17.2.2.2 Approach 2: Study of annual reports and investor presentations
- 17.2.2.3 Approach 3: Primary interviews
- 17.2.2.4 Growth forecast
- 17.2.3 TOP-DOWN APPROACH
- 17.3 DATA TRIANGULATION
- 17.4 RESEARCH ASSUMPTIONS
- 17.4.1 STUDY-RELATED ASSUMPTIONS
- 17.4.2 GROWTH RATE ASSUMPTIONS
- 17.5 RESEARCH LIMITATIONS
- 17.6 RISK ASSESSMENT
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS
List of Tables
- TABLE 1 INCLUSIONS & EXCLUSIONS
- TABLE 2 CANCER/TUMOR PROFILING MARKET: PORTER'S FIVE FORCES ANALYSIS
- TABLE 3 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2023-2030
- TABLE 4 NORTH AMERICA: MACROECONOMIC INDICATORS
- TABLE 5 EUROPE: MACROECONOMIC INDICATORS
- TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS
- TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS
- TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
- TABLE 9 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY KEY PLAYER, 2024-2026 (USD)
- TABLE 10 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION, 2024-2026 (USD)
- TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
- TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
- TABLE 13 CANCER/TUMOR PROFILING MARKET: KEY CONFERENCES & EVENTS, 2026-2027
- TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES
- TABLE 15 KEY COMPANIES IMPLEMENTING AI IN CANCER/TUMOR PROFILING MARKET
- TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE
- TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
- TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
- TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
- TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
- TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES
- TABLE 27 CANCER/TUMOR PROFILING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
- TABLE 28 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 29 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 30 NORTH AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 31 EUROPE: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 32 ASIA PACIFIC: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 33 LATIN AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 34 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 35 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 36 CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 37 NORTH AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 38 EUROPE: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 39 ASIA PACIFIC: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 40 LATIN AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 41 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 42 CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 43 NORTH AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 44 EUROPE: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 45 ASIA PACIFIC: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 46 LATIN AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 47 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 48 CANCER/TUMOR PROFILING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 49 NORTH AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 50 EUROPE: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 51 ASIA PACIFIC: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 52 LATIN AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 53 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 54 CANCER/TUMOR PROFILING SERVICES MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 55 CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 56 NORTH AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 57 EUROPE: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 58 ASIA PACIFIC: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 59 LATIN AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 60 MIDDLE EAST & AFRICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 61 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 62 NORTH AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 63 EUROPE: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 64 ASIA PACIFIC: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 65 LATIN AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 66 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 67 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 68 CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 69 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 70 EUROPE: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 71 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 72 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 73 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 74 CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 76 EUROPE: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 77 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 78 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 79 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 80 CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 82 EUROPE: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 83 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 84 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 85 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 86 CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 87 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 88 EUROPE: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 89 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 90 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 91 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 92 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 93 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 94 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 95 EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 96 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 97 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 98 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 99 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 100 CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY REGION, 2024-2031 (USD MILLION)
- TABLE 101 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 102 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 103 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 104 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 105 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 106 CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 107 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 108 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 109 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 110 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 111 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 112 CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 113 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 115 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 116 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 117 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 118 CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY REGION, 2024-2031 (USD MILLION)
- TABLE 119 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 121 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 122 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 123 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 124 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 125 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 126 EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 127 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 128 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 129 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 130 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 131 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 132 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 133 EUROPE: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 134 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 135 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 136 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/ REGION, 2024-2031 (USD MILLION)
- TABLE 137 CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY REGION, 2024-2031 (USD MILLION)
- TABLE 138 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 139 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 140 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 141 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 142 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 143 CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY REGION, 2024-2031 (USD MILLION)
- TABLE 144 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 145 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 146 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 147 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 148 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 149 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 150 SOLID TUMOR PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 151 NORTH AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 152 EUROPE: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 153 ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 154 LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 155 MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/ REGION, 2024-2031 (USD MILLION)
- TABLE 156 SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 157 LUNG CANCER PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 158 NORTH AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 159 EUROPE: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 160 ASIA PACIFIC: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 161 LATIN AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 162 MIDDLE EAST & AFRICA: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 163 BREAST CANCER PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 164 NORTH AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 165 EUROPE: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 166 ASIA PACIFIC: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 167 LATIN AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 168 MIDDLE EAST & AFRICA: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 169 COLORECTAL CANCER PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 170 NORTH AMERICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 171 EUROPE: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 172 ASIA PACIFIC: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 173 LATIN AMERICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 174 MIDDLE EAST & AFRICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 175 PROSTATE CANCER PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 176 NORTH AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 177 EUROPE: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 178 ASIA PACIFIC: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 179 LATIN AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 180 MIDDLE EAST & AFRICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 181 GYNECOLOGIC CANCERS PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 182 NORTH AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 183 EUROPE: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 184 ASIA PACIFIC: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 185 LATIN AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 186 MIDDLE EAST & AFRICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 187 MELANOMA PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 188 NORTH AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 189 EUROPE: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 190 ASIA PACIFIC: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 191 LATIN AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 192 MIDDLE EAST & AFRICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 193 BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 194 NORTH AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 195 EUROPE: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 196 ASIA PACIFIC: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 197 LATIN AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 198 MIDDLE EAST & AFRICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 199 HEAD AND NECK CANCER PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 200 NORTH AMERICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 201 EUROPE: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 202 ASIA PACIFIC: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 203 LATIN AMERICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 204 MIDDLE EAST & AFRICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 205 OTHER SOLID TUMOR PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 206 NORTH AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 207 EUROPE: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 208 ASIA PACIFIC: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 209 LATIN AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 210 MIDDLE EAST & AFRICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 211 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 212 NORTH AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 213 EUROPE: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 214 ASIA PACIFIC: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 215 LATIN AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 216 MIDDLE EAST & AFRICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 217 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 218 LEUKEMIA PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 219 NORTH AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 220 EUROPE: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 221 ASIA PACIFIC: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 222 LATIN AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 223 MIDDLE EAST & AFRICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 224 LYMPHOMA PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 225 NORTH AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 226 EUROPE: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 227 ASIA PACIFIC: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 228 LATIN AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 229 MIDDLE EAST & AFRICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 230 MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 231 NORTH AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 232 EUROPE: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 233 ASIA PACIFIC: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 234 LATIN AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 235 MIDDLE EAST & AFRICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 236 CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 237 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 238 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 239 EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 240 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 241 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 242 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 243 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 244 CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 245 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 246 EUROPE: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 247 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 249 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 250 CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 251 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 252 EUROPE: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 253 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 254 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 255 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 256 CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 257 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 258 EUROPE: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 259 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 260 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 261 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 262 CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 263 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 264 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 265 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 266 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 267 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/ REGION, 2024-2031 (USD MILLION)
- TABLE 268 CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 269 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 270 EUROPE: CANCER/TUMOR PROFILING MARKET CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 271 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 272 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 273 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 274 CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 275 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 276 EUROPE: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 277 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 278 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 279 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024-2031 (USD MILLION)
- TABLE 280 CANCER/TUMOR PROFILING MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 281 NORTH AMERICA: MACROECONOMIC INDICATORS
- TABLE 282 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 283 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 284 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 285 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 286 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 287 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 288 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 289 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 290 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 291 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 292 NORTH AMERICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 293 NORTH AMERICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 294 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 295 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 296 US: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 297 US: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 298 US: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 299 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 300 US: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 301 US: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 302 US: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 303 US: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 304 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 305 US: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 306 US: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 307 US: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 308 US: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 309 CANADA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 310 CANADA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 311 CANADA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 312 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 313 CANADA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 314 CANADA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 315 CANADA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 316 CANADA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 317 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 318 CANADA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 319 CANADA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 320 CANADA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 321 CANADA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 322 EUROPE: MACROECONOMIC INDICATORS
- TABLE 323 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 324 EUROPE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 325 EUROPE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 326 EUROPE: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 327 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 328 EUROPE: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 329 EUROPE: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 330 EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 331 EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 332 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 333 EUROPE: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 334 EUROPE: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 335 EUROPE: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 336 EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 337 GERMANY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 338 GERMANY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 339 GERMANY: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 340 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 341 GERMANY: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 342 GERMANY: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 343 GERMANY: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 344 GERMANY: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 345 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 346 GERMANY: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 347 GERMANY: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 348 GERMANY: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 349 GERMANY: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 350 UK: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 351 UK: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 352 UK: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 353 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 354 UK: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 355 UK: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 356 UK: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 357 UK: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 358 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 359 UK: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 360 UK: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 361 UK: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 362 UK: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 363 FRANCE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 364 FRANCE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 365 FRANCE: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 366 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 367 FRANCE: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 368 FRANCE: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 369 FRANCE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 370 FRANCE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 371 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 372 FRANCE: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 373 FRANCE: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 374 FRANCE: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 375 FRANCE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 376 ITALY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 377 ITALY: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 378 ITALY: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 379 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 380 ITALY: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 381 ITALY: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 382 ITALY: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 383 ITALY: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 384 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 385 ITALY: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 386 ITALY: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 387 ITALY: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 388 ITALY: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 389 SPAIN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 390 SPAIN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 391 SPAIN: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 392 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 393 SPAIN: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 394 SPAIN: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 395 SPAIN: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 396 SPAIN: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 397 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 398 SPAIN: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 399 SPAIN: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 400 SPAIN: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 401 SPAIN: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 402 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 403 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 404 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 405 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 406 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 407 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 408 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 409 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 410 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 411 REST OF EUROPE: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 412 REST OF EUROPE: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 413 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 414 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 415 ASIA PACIFIC: MACROECONOMIC INDICATORS
- TABLE 416 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 417 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 418 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 419 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 420 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 421 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 422 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 423 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 424 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 425 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 426 ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 427 ASIA PACIFIC: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 428 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 429 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 430 CHINA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 431 CHINA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 432 CHINA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 433 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 434 CHINA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 435 CHINA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 436 CHINA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 437 CHINA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 438 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 439 CHINA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 440 CHINA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 441 CHINA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 442 CHINA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 443 JAPAN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 444 JAPAN: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 445 JAPAN: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 446 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 447 JAPAN: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 448 JAPAN: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 449 JAPAN: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 450 JAPAN: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 451 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 452 JAPAN: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 453 JAPAN: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 454 JAPAN: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 455 JAPAN: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 456 INDIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 457 INDIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 458 INDIA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 459 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 460 INDIA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 461 INDIA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 462 INDIA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 463 INDIA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 464 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 465 INDIA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 466 INDIA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 467 INDIA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 468 INDIA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 469 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 470 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 471 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 472 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 473 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 474 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 475 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 476 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 477 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 478 SOUTH KOREA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 479 SOUTH KOREA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 480 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 481 SOUTH KOREA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 482 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 483 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 484 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 485 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 486 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 487 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 488 AUSTRALIA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 489 AUSTRALIA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 490 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 491 AUSTRALIA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 492 AUSTRALIA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 493 AUSTRALIA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 494 AUSTRALIA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 495 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 496 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 497 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 498 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 499 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 500 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 501 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 502 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 503 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 504 REST OF ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 505 REST OF ASIA PACIFIC: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 506 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 507 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 508 LATIN AMERICA: MACROECONOMIC INDICATORS
- TABLE 509 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 510 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 511 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 512 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 513 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 514 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 515 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 516 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 517 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 518 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 519 LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 520 LATIN AMERICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 521 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 522 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 523 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 524 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 525 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 526 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 527 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 528 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 529 BRAZIL: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 530 BRAZIL: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 531 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 532 BRAZIL: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 533 BRAZIL: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 534 BRAZIL: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 535 BRAZIL: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 536 MEXICO: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 537 MEXICO: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 538 MEXICO: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 539 MEXICO: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 540 MEXICO: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 541 MEXICO: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 542 MEXICO: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 543 MEXICO: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 544 MEXICO: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 545 MEXICO: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 546 MEXICO: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 547 MEXICO: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 548 MEXICO: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 549 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 550 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 551 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 552 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 553 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 554 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 555 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 556 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 557 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 558 REST OF LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 559 REST OF LATIN AMERICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 560 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 561 REST OF LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 562 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 563 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 564 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 565 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 566 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 567 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 568 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 569 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 570 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 571 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 572 MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 573 MIDDLE EAST & AFRICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 574 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 575 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 576 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 577 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 578 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 579 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 580 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 581 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 582 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 583 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 584 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 585 GCC COUNTRIES: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 586 GCC COUNTRIES: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 587 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 588 GCC COUNTRIES: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 589 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024-2031 (USD MILLION)
- TABLE 590 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
- TABLE 591 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2024-2031 (USD MILLION)
- TABLE 592 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
- TABLE 593 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024-2031 (USD MILLION)
- TABLE 594 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 595 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 596 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024-2031 (USD MILLION)
- TABLE 597 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024-2031 (USD MILLION)
- TABLE 598 REST OF MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 599 REST OF MIDDLE EAST & AFRICA: LIQUID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024-2031 (USD MILLION)
- TABLE 600 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 601 REST OF MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 602 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CANCER/TUMOR PROFILING MARKET, JANUARY 2023-AUGUST 2026
- TABLE 603 CANCER/TUMOR PROFILING MARKET: DEGREE OF COMPETITION
- TABLE 604 CANCER/TUMOR PROFILING MARKET: REGIONAL FOOTPRINT
- TABLE 605 CANCER/TUMOR PROFILING MARKET: PRODUCT & SERVICE FOOTPRINT
- TABLE 606 CANCER/TUMOR PROFILING MARKET: TECHNOLOGY FOOTPRINT
- TABLE 607 CANCER/TUMOR PROFILING MARKET: SAMPLE TYPE FOOTPRINT
- TABLE 608 CANCER/TUMOR PROFILING MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2025
- TABLE 609 CANCER/TUMOR PROFILING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2), 2025
- TABLE 610 CANCER/TUMOR PROFILING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2), 2025
- TABLE 611 CANCER TUMOR PROFILING MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 612 CANCER/TUMOR PROFILING MARKET: DEALS, JANUARY 2023-MAY 2026
- TABLE 613 CANCER/TUMOR PROFILING MARKET: EXPANSIONS, JANUARY 2023-AUGUST 2026
- TABLE 614 CANCER/TUMOR PROFILING MARKET: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
- TABLE 615 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
- TABLE 616 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
- TABLE 617 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 618 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 619 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023-AUGUST 2026
- TABLE 620 ILLUMINA, INC.: COMPANY OVERVIEW
- TABLE 621 ILLUMINA, INC.: PRODUCTS OFFERED
- TABLE 622 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 623 ILLUMINA, INC.: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 624 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
- TABLE 625 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
- TABLE 626 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
- TABLE 627 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
- TABLE 628 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 629 QIAGEN: COMPANY OVERVIEW
- TABLE 630 QIAGEN: PRODUCTS OFFERED
- TABLE 631 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 632 QIAGEN: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 633 QIAGEN: EXPANSIONS, JANUARY 2023-AUGUST 2026
- TABLE 634 GUARDANT HEALTH: COMPANY OVERVIEW
- TABLE 635 GUARDANT HEALTH: PRODUCTS OFFERED
- TABLE 636 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 637 GUARDANT HEALTH: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 638 LABCORP: COMPANY OVERVIEW
- TABLE 639 LABCORP: SERVICES OFFERED
- TABLE 640 LABCORP: SERVICE LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 641 LABCORP: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 642 LABCORP: EXPANSIONS, JANUARY 2023-AUGUST 2026
- TABLE 643 ABBOTT: COMPANY OVERVIEW
- TABLE 644 ABBOTT: PRODUCTS OFFERED
- TABLE 645 ABBOTT: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 646 ABBOTT: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 647 TEMPUS AI, INC.: COMPANY OVERVIEW
- TABLE 648 TEMPUS AI, INC.: PRODUCTS OFFERED
- TABLE 649 TEMPUS AI, INC: PRODUCT APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 650 TEMPUS AI, INC.: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 651 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
- TABLE 652 NATERA, INC.: COMPANY OVERVIEW
- TABLE 653 NATERA, INC.: PRODUCTS OFFERED
- TABLE 654 NATERA, INC.: PRODUCT LAUNCHES, JANUARY 2023-AUGUST 2026
- TABLE 655 NATERA, INC.: DEALS JANUARY 2023-AUGUST 2026
- TABLE 656 NATERA, INC: EXPANSIONS, JANUARY 2023-AUGUST 2026
- TABLE 657 NATERA, INC.: OTHER DEVELOPMENTS, JANUARY 2023-AUGUST 2026
- TABLE 658 NEOGENOMICS LABORATORIES, INC: COMPANY OVERVIEW
- TABLE 659 NEOGENOMICS LABORATORIES, INC: PRODUCTS OFFERED
- TABLE 660 NEOGENOMICS LABORATORIES, INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 661 NEOGENOMICS LABORATORIES, INC: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 662 NEOGENOMICS LABORATORIES, INC: EXPANSIONS, JANUARY 2023-AUGUST 2026
- TABLE 663 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
- TABLE 664 MYRIAD GENETICS, INC.: PRODUCTS OFFERED
- TABLE 665 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 666 MYRIAD GENETICS, INC.: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 667 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
- TABLE 668 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
- TABLE 669 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 670 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 671 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023-AUGUST 2026
- TABLE 672 QUEST DIAGNOSTICS: COMPANY OVERVIEW
- TABLE 673 QUEST DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
- TABLE 674 QUEST DIAGNOSTICS: PRODUCT/SERVICES LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 675 QUEST DIAGNOSTICS: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 676 CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW
- TABLE 677 CARIS LIFE SCIENCES, INC.: PRODUCTS OFFERED
- TABLE 678 CARIS LIFE SCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-AUGUST 2026
- TABLE 679 CARIS LIFE SCIENCES, INC.: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 680 DANAHER: COMPANY OVERVIEW
- TABLE 681 DANAHER: PRODUCTS OFFERED
- TABLE 682 DANAHER: DEALS, JANUARY 2023-AUGUST 2026
- TABLE 683 KEY DATA FROM PRIMARY SOURCES
- TABLE 684 STUDY ASSUMPTIONS
- TABLE 685 CANCER/TUMOR PROFILING MARKET: RISK ASSESSMENT
List of Figures
- FIGURE 1 CANCER/TUMOR PROFILING MARKET SEGMENTATION & REGIONAL SCOPE
- FIGURE 2 STUDY YEARS CONSIDERED
- FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS
- FIGURE 4 GLOBAL CANCER/TUMOR PROFILING MARKET, 2024-2031
- FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023-2025
- FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER/TUMOR PROFILING MARKET
- FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN CANCER/TUMOR PROFILING MARKET, 2025
- FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
- FIGURE 9 INCREASING ADOPTION OF PRECISION ONCOLOGY TO DRIVE MARKET
- FIGURE 10 PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
- FIGURE 11 ASSAYS, KITS & REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
- FIGURE 12 CLINICAL TUMOR PROFILING TESTING SERVICES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
- FIGURE 13 NEXT GENERATION SEQUENCING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 14 TISSUE SAMPLE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 15 CLINICAL APPLICATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 16 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION AND PROGNOSTIC/RISK ASSESSMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 17 BIOMARKER, TARGET AND EARLY DRUG DISCOVERY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 18 SOLID TUMOR SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 19 LUNG CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 20 LEUKEMIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 21 HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 22 DEDICATED CANCER HOSPITALS AND CANCER CENTERS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
- FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
- FIGURE 24 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 25 CANCER/TUMOR PROFILING MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 26 CANCER/TUMOR PROFILING MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 27 CANCER/ TUMOR PROFILING MARKET: VALUE CHAIN ANALYSIS
- FIGURE 28 CANCER/TUMOR PROFILING MARKET: ECOSYSTEM ANALYSIS
- FIGURE 29 CANCER/TUMOR PROFILING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- FIGURE 30 NUMBER OF DEALS & FUNDING ACTIVITIES OF KEY PLAYERS IN THE CANCER/TUMOR PROFILING MARKET
- FIGURE 31 PATENT ANALYSIS FOR CANCER/TUMOR PROFILING MARKET, JANUARY 2016-DECEMBER 2025
- FIGURE 32 MARKET POTENTIAL OF AI IN CANCER/TUMOR PROFILING MARKET
- FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE OFFERING
- FIGURE 34 KEY BUYING CRITERIA, BY PRODUCT & SERVICE OFFERING
- FIGURE 35 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
- FIGURE 36 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
- FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023-2025 (USD MILLION)
- FIGURE 38 CANCER/TUMOR PROFILING MARKET SHARE ANALYSIS, 2025 (GLOBAL)
- FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
- FIGURE 40 CANCER/TUMOR PROFILING MARKET: COMPANY FOOTPRINT
- FIGURE 41 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
- FIGURE 42 EV/EBITDA OF KEY VENDORS
- FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 44 CANCER/TUMOR PROFILING MARKET: BRAND/PRODUCT COMPARISON FOR CANCER/TUMOR PROFILING
- FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
- FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
- FIGURE 48 QIAGEN: COMPANY SNAPSHOT (2025)
- FIGURE 49 GUARDANT HEALTH: COMPANY SNAPSHOT (2025)
- FIGURE 50 LABCORP: COMPANY SNAPSHOT (2025)
- FIGURE 51 ABBOTT: COMPANY SNAPSHOT (2025)
- FIGURE 52 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 53 NATERA, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 54 NEOGENOMICS LABORATORIES, INC: COMPANY SNAPSHOT (2025)
- FIGURE 55 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 57 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2025)
- FIGURE 58 CARIS LIFE SCIENCES, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 59 DANAHER: COMPANY SNAPSHOT (2025)
- FIGURE 60 RESEARCH DESIGN
- FIGURE 61 KEY DATA FROM SECONDARY SOURCES
- FIGURE 62 LIST OF PRIMARY SOURCES
- FIGURE 63 KEY INDUSTRY INSIGHTS
- FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 65 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
- FIGURE 66 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026-2031): IMPACT ON MARKET GROWTH AND CAGR
- FIGURE 67 CAGR PROJECTIONS
- FIGURE 68 TOP-DOWN APPROACH
- FIGURE 69 DATA TRIANGULATION
- FIGURE 70 PARAMETRIC ASSUMPTIONS
